As expected [14, 17, 52–55], individuals of the AD group showed the most consistent increase in plasma GFAP levels, allowing their discrimination from the other disease group with an overall moderate accuracy (AUC 0.578–0.818), although lower than that shown by p-tau181. Here, GFAP is linked to Alzheimer disease.